. 2025 Apr 9;19(4):e0012993. doi: 10.1371/journal.pntd.0012993

Table 7. Logistic models to high^* neutralizing antibody titer for yellow fever 30–45 days after vaccination in adults (between 18 and 50 years) (n = 240).

Variables	Crude OR (95% CI)	Adjusted OR^** (95% CI)
μFRNT dengue pre-vaccination
Positive	0.35 (0.15–0.76)	0.34 (0.14–0.74)
Negative	1	1
PRNT₉₀ Zika pre-vaccination
Positive	1.51 (0.49–6.64)	2.06 (0.64–9.22)
Negative	1	1
Age (year)	1.02 (0.98–1.07)	1.02 (0.98–1.06)

Pre-vaccine yellow fever seropositive individuals and individuals who had seronegative and indeterminate titers 30–45 days post-vaccination were excluded; Data from the subsample of participants tested for μFRNT dengue and PRNT₉₀ Zika.

Reference category: μFRNT YF ≤1.106 (low).

^**

Model adjusted by μFRNT dengue pre-vaccination, PRNT₉₀ Zika pre-vaccination, Age (years) and sex: AIC = 230.

Table 7. Logistic models to high* neutralizing antibody titer for yellow fever 30–45 days after vaccination in adults (between 18 and 50 years) (n = 240).

Table 7. Logistic models to high^* neutralizing antibody titer for yellow fever 30–45 days after vaccination in adults (between 18 and 50 years) (n = 240).